WO2021176409A1 - Combinaison de conservateurs pour composition de vaccin - Google Patents

Combinaison de conservateurs pour composition de vaccin Download PDF

Info

Publication number
WO2021176409A1
WO2021176409A1 PCT/IB2021/051848 IB2021051848W WO2021176409A1 WO 2021176409 A1 WO2021176409 A1 WO 2021176409A1 IB 2021051848 W IB2021051848 W IB 2021051848W WO 2021176409 A1 WO2021176409 A1 WO 2021176409A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine composition
amount
formaldehyde
antigen
phenoxyethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/051848
Other languages
English (en)
Inventor
Kilvani Semburakkiannan JAGANATHAN
Raju Radhakrishnam MANTENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Healthcare India Pvt Ltd
Original Assignee
Sanofi Healthcare India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Healthcare India Pvt Ltd filed Critical Sanofi Healthcare India Pvt Ltd
Publication of WO2021176409A1 publication Critical patent/WO2021176409A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a combination of preservatives for vaccine composition or formulation, more particularly a combination of 2-phenoxyethanol and formaldehyde.
  • Preservatives are generally used in multi-dose presentations of vaccines to prevent contamination due to repeated withdrawal of the vaccine doses from the container. However, it does not preclude the use of preservative in the single dose presentation of the vaccine.
  • a preservative which is commonly used in pharmaceutical preparations, including vaccines, is 2- phenoxyethanol or 2-PE ⁇ Meyer, Brian K. et al. Journal of Pharmaceutical Sciences (2007) 96: 3155- 3167).
  • 2-PE 2- phenoxyethanol
  • One of the reasons prompting the use of 2-PE in several of the DTP combination vaccines probably has to do with the presence of IPV antigen in them.
  • W02008020322 describes a process of making a combination vaccine comprising diphtheria and tetanus toxoid with 2-PE and mixing these components with another antigen.
  • WO1998034594 discloses a preservative combination having 2-PE along with methyl and propyl paraben.
  • W02020021416 discloses a preservative system which is free of thimerosal and comprising 2-PE and at least one other preservative selected form m-cresol, benzyl alcohol, phenol and benzoic acid.
  • Hekkens, F.E.N. et al. discloses a preservative combination having 2-PE and formaldehyde. Hekkens, F.E.N. et. al. used 0.5% 2-PE in combination with formaldehyde at either 25, 50, 75 pg/mL and recommends such a combination to be employed for polio antigen containing combination vaccines.
  • W02017048038 discloses a preservative combination having 2-PE along with formaldehyde at a concentration of at least 7 mg/mL and 120 pg/mL respectively as an effective preservative concentration.
  • IN201917040656 discloses a polyvalent pneumococcal vaccine composition comprising a preservative combination having at least 4 mg/mL 2-PE and at least 90 pg/mL formaldehyde.
  • Formaldehyde has been known to cross link proteins, and increasing the concentration of formaldehyde may compromise the stability and immunogenicity of the antigens contained in the vaccine composition.
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxyethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025%.
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxyethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%.
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxyethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, and the vaccine composition is presented either in a single dose container or a multi dose container.
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxyethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, and wherein the vaccine composition comprises one or more antigens.
  • the invention relates to a vaccine composition comprising 2-phenoxythanol (2-PE) and formaldehyde, wherein the 2-PE is present in an amount of 0.4% to 0.7% and the formaldehyde is present in an amount from 0.0002% to 0.0024%.
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxy ethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%
  • the vaccine composition comprises at least one antigen selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), flavivirus (FV), human papillomavirus (HPV).
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • HAV hepatitis
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxy ethanol (2-PE) and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, and wherein the vaccine composition comprises antigens selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV).
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxy ethanol (2-PE) and formaldehyde, wherein the 2-phenoxyethanol is present in an amount from 0.4% to 0.7% and the formaldehyde is present in an amount from 0.0002% to 0.0024%
  • the vaccine composition comprises antigens selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV).
  • the invention relates to a vaccine composition
  • a vaccine composition comprising 2-phenoxy ethnaol and formaldehyde, wherein the formaldehyde is present in an amount of 0.0002% to 0.0014% and the 2-phenoxyethanol is present in an amount from 0.5% to 0.6%
  • the vaccine composition comprises antigens selected from the group comprising of diphtheria (D), tetanus (T), whole cell pertussis (wP), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV).
  • the invention also relates to a method of preparing a vaccine composition comprising 2- phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, exogenously to the vaccine composition.
  • the invention also relates to a method of preparing a vaccine composition comprising 2- phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, endogenously to the vaccine composition.
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethnaol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding partial amount of 2-phenoxyethanol, formaldehyde, or both, endogenously to the vaccine composition.
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding partial amount of 2-phenoxyethnaol, formaldehyde, or both, exogenously to the vaccine composition.
  • the invention also relates to a method of preparing a vaccine composition
  • a method of preparing a vaccine composition comprising 2- phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%
  • the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, either exogenously or endogenously, to the vaccine composition, wherein the method further comprises a step of adding at least one antigen selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), fla
  • the invention also relates to a method of preparing a vaccine composition comprising 2- phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding partial amount of 2-phenoxyethanol, formaldehyde, or both, either exogenously or endogenously, to the vaccine composition, wherein the method further comprises a step of adding at least one antigen selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), flavivirus (FV), and human
  • composition has been used interchangeably to mean a composition comprising one or more antigens and/or one or more excipients.
  • antigen means a component of a formulation or composition which is responsible for stimulating an immune response i.e., generation of antibodies against it when administered to an animal or human.
  • excipient means a component of a composition or formulation other than an antigen.
  • the term “container” as used herein means a receptacle for holding the vaccine composition, for example, a vial or a syringe or an analogous device.
  • the amount of 2-phenoxyethanol and/or formaldehyde present in the vaccine composition or formulation is typically the amount present in a dose of the vaccine composition.
  • dose means a volume of dose that is targeted to be administered to a subject such as an animal or human subject, and does not include any excess fill volume or overages that may be added to the targeted dose.
  • suitable dosage volumes may be in a range between 0.1 mL to 1.0 mL, 0.2 to 0.8 mL, 0.3 to 0.6 mL or preferably 0.5 mL.
  • not adsorbed or “un-adsorbed” or any variant thereof as used herein means there is no specific attempt made to adsorb an agent, such as an antigen, onto an adjuvant. However, it does not exclude any adsorption of an antigen onto an adjuvant that may happen without any deliberate steps being taken i.e., when the antigens are added to the formulation not intended to be adsorbed, or during the storage of the vaccine composition.
  • endogenous or “endogenously” or any variant thereof as used herein in the context of preservatives denotes the presence or inclusion or addition of one or both of the preservatives during the manufacturing process of one or more antigens or their addition to one or more of the bulk antigens in total or partial amounts in accordance with the invention.
  • preservatives i.e., 2-phenoxyethanol or formaldehyde
  • one or both of the preservatives may be totally or partially contributed by the manufacturing process of one or more antigens or present with one or more of the bulk antigens, and consequently may or may not require, depending upon the amount present, exogenous addition of one or both of the preservatives to the vaccine composition.
  • exogenous or “exogenously” or any variant thereof as used herein in the context of one or both of the preservatives (i.e., 2-phenoxyethanol or formaldehyde) denotes the addition of one or both of the preservatives to one or more antigens or mixture of antigens at the time of preparing the vaccine composition.
  • addition means the step of combining or mixing one component with another component of the vaccine composition i.e., combining or mixing one or both of the preservatives, one or more antigens, or any other excipient(s) in no particular order.
  • component “X” is added to component “Y” it not only means addition of component “X” to “Y”, but also vice versa.
  • compositions or formulation The amount of preservative contained in the composition or formulation is expressed either as v/v or w/v and is apparent to a person skilled in the art.
  • the invention provides a vaccine composition comprising 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.002%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0018%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0016%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0014%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0012%.
  • the invention provides a vaccine composition comprising 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025%.
  • the formaldehyde is present in an amount of less than 0.0025%, equal to or less than 0.0018%, equal to or less than 0.0016%, equal to or less than 0.0014%, equal to or less than 0.0013%, or equal to or less than 0.00125%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.002%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0018%. In one of the embodiments, a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0016%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0014%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0012%.
  • the 2-phenoxyethanol is present at a concentration of 0.5-0.6%.
  • the vaccine composition comprising 2-phenoxyethanol and formaldehyde of the invention may be used for a variety of vaccine compositions, viz., monovalent or multivalent (combination) vaccines.
  • the term “monovalent” herein means a vaccine composition comprising one or more antigens derived from a single species or targeting the same disease, whereas the term “multivalent’ herein means a vaccine composition comprising two or more antigens derived from different species or targeting two or more diseases.
  • Such monovalent and multivalent vaccines and their method of preparation is well known in the art.
  • a variety of antigens may be included in the vaccine composition in accordance with the invention.
  • Diphtheria antigen is typically diphtheria toxoid which can be obtained from Corynebacterium diphtheriae.
  • the method of culturing Corynebacterium diphtheriae, purification of diphtheria toxin and its inactivation or detoxification to obtain diphtheria toxoid are well known to a person skilled in the art (Manual for the production and control of vaccines: diphtheria toxoid, World Health Organization, B LG/UNDP/77.1 Rev.l (1977); US3135662; W02006100108).
  • diphtheria toxoid is prepared by growing a strain of Corynebacterium diphtheriae in a fermenter containing suitable medium.
  • diphtheria toxin produced by the bacterium is extracted and purified, followed by its inactivation by treating with chemicals such as formaldehyde or glutaraldehyde to obtain diphtheria toxoid.
  • the diphtheria toxin after extraction may be first inactivated and then purified to obtain the diphtheria toxoid.
  • diphtheria toxoid is present at an amount of 5-50 Lf, 10-30 Lf, or 10-20 Lf per dose, preferably as a 0.5 mL dosage volume.
  • diphtheria toxoid is adsorbed onto an aluminium adjuvant, either aluminium hydroxide or aluminium phosphate or a mixture of both.
  • diphtheria toxoid is a component of the monovalent or multivalent vaccine composition.
  • Tetanus antigen is typically tetanus toxoid which can be obtained from Clostridium tetani.
  • the method of culturing Clostridium tetani, purification of tetanus toxin and its inactivation or detoxification to obtain tetanus toxoid are well known to a person skilled in the art (Manual for the production and control of vaccines: tetanus toxoid, World Health Organization BLG/UNDP/77.2 Rev.l (1977); Fratelli, Fernando et al. Biotechnology Progress (2010) 26: 88-92; US6060067).
  • tetanus toxoid is prepared by growing a strain of Clostridium tetani in a fermenter containing suitable medium.
  • the tetanus toxin produced by the bacterium is extracted and purified, followed by its inactivation by treating with chemicals such as formaldehyde or glutaraldehyde to obtain tetanus toxoid.
  • the tetanus toxin after extraction may be first inactivated and then purified to obtain the tetanus toxoid.
  • tetanus toxoid is present at an amount of 2-30 Lf, 5-20, 5-15 Lf or 5-10 Lf per dose, preferably as a 0.5 mL dosage volume.
  • tetanus toxoid is adsorbed onto an aluminium adjuvant, either aluminium hydroxide or aluminium phosphate or a mixture of both.
  • tetanus toxoid is a component of the monovalent or multivalent vaccine composition.
  • Pertussis antigen is obtained from Bordetella pertussis and can either be cellular (whole cell pertussis - wP) or acellular (purified pertussis components or acellular pertussis - aP). Preparation of whole cell pertussis (wP) is well known in the art. It is generally produced by culturing a strain of Bordetella pertussis and inactivating or detoxifying the wP by heat or chemicals or a combination of both (Manual for the production and control of vaccines: pertussis vaccine, World Health Organization, B LG/UNDP/77.3 Rev.l (1977); Gupta, R.K. et al.
  • formaldehyde, glutaraldehyde, acetone or their combination is used.
  • Thimerosal is recommended to be avoided.
  • the residual thimerosal may be removed by treating the suspension of wP with compounds such as EDTA, or cysteine.
  • wP is inactivated by heat. In another embodiment, wP is inactivated by chemicals, preferably formaldehyde. In one of the embodiments, wP is inactivated preferably by glutaraldehyde. In one of the embodiments, wP is inactivated by a combination of heat and chemicals. In one of the embodiments, wP is present at an amount of 5-50 IOU, 10-40 IOU, or 10-25 IOU per dose, preferably as a 0.5 mL dosage volume. In one of the embodiments, whole cell pertussis (wP) is a component of the monovalent or multivalent vaccine composition.
  • Acellular pertussis (aP) antigen may comprise one or more immunogenic components from Bordetella pertussis such as pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), fimbrial antigens such as Fim 2, & 3.
  • Bordetella pertussis such as pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), fimbrial antigens such as Fim 2, & 3.
  • Acellular pertussis components may be obtained by culturing a strain of Bordetella pertussis, followed by their purification and inactivation. Such methods are well known in the art (W098/00167).
  • pertussis toxoid is present at an amount of 2-50, 5-40, 10-30 microgram per dose, preferably as a 0.5 mL dosage volume.
  • FHA is present at an amount of 2-50, 5-40, 10-30 microgram per dose, preferably as a 0.5 mL dosage volume.
  • PRN is present at an amount of 1-10, 2-8, 2-6, microgram per dose, preferably as a 0.5 mL dosage volume.
  • Fim2 and Fim3 are present at an amount of 1-10, 2-8, 2-7 microgram per dose, preferably as a 0.5 mL dosage volume.
  • pertussis components may be adsorbed onto aluminium adjuvant, either aluminium hydroxide or aluminium phosphate or a mixture of both.
  • one or more aP components are part of the monovalent or multivalent vaccine composition.
  • Hib antigen used in the present invention is a capsular polysaccharide of Haemophilus influenzae type b conjugated to carrier protein.
  • Methods of preparing such polysaccharide protein conjugates are well known to a person skilled in the art.
  • the polysaccharide protein conjugate may be prepared by covalently attaching purified capsular polysaccharides to carrier protein using a variety of chemical methods.
  • the polysaccharide protein conjugate may be prepared as described by Schneerson, R. et al. (1980) J. Exp. Med. 152: 361-476; Chit, chiayung et al. (1983) Infection and Immunity 40(1): 245-256.
  • the polysaccharide (PS) is first activated in the presence of cyanogen bromide to generate a cyanate ester.
  • the activated polysaccharide is then linked (derivatized) to the spacer, for example, adipic dihydrazide (AH). It is also possible to directly link spacer without activation of the polysaccharide.
  • the derivatized polysaccharide (PS-AH) is conjugated to the carrier protein using carbodiimides such as l-ethyl-3-(3-dimethylaminopropyl (EDAC or EDC), N,N- Dicyclohexyl carbodiimide (DCC), or N,N-Diisopropyl carbodiimide (DIC).
  • Activation of polysaccharide may also be achieved by organic cyanylating agents such as l-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP), N- cyanotriethylammonium tetrafluoroborate (CTEA), and p_Nitrophenylcyanate (pNPC) as described by Lees, Andrew US5693326; Lees, Andrew et al. (1996) Vaccine 14(3): 190-198.
  • organic cyanylating agents such as l-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP), N- cyanotriethylammonium tetrafluoroborate (CTEA), and p_Nitrophenylcyanate (pNPC) as described by Lees, Andrew US5693326; Lees, Andrew et al. (1996) Vaccine 14(3): 190-198.
  • polysaccharides, or fragments thereof may be activated selectively at their terminal reducing ends by introducing aldehydes which may be directly or indirectly (through a linker or spacer) coupled to carrier protein by reductive amination to obtain the conjugate ( Jennings , H. J. US4356170; P. W. Anderson, et al. (1986) J. Immunol. 137: 1181-1186; Gray GR. (1978) Methods Enzymology; 50: 155-160).
  • Hib is present in an amount of 2-20, 5-18, 7-15 microgram per dose, preferably as a 0.5 mL dosage volume.
  • Hib may be adsorbed onto an aluminium adjuvant.
  • Hib is not adsorbed onto an aluminium adjuvant. It is preferable that Hib is not adsorbed onto any adjuvant or remains un-adsorbed onto any adjuvant. However, it is entirely possible that some amount of Hib may get adsorbed onto the adjuvant passively i.e., without any deliberate attempt of adsorbing the Hib antigen.
  • Hib is a component of the monovalent or multivalent vaccine composition.
  • Hepatitis B HepB
  • Hepatitis B antigen is obtained from Hepatitis B virus and is generally the surface protein of Hepatitis B Virus viz., Hepatitis B surface Antigen (HBsAg).
  • HBsAg Hepatitis B surface Antigen
  • Methods of preparing HBsAg are well known to a person skilled in the art.
  • HBsAg may be obtained by purifying the hepatitis b particle from the plasma of chronic hepatitis B carriers. More commonly, HBsAg is obtained by recombinant DNA technology by expressing the HBsAg gene in an expression system (bacterial, yeast or mammalian expression system).
  • the bacterium or yeast or mammalian cells carrying the HBsAg gene is grown in culture medium and HBsAg is purified through a series of downstream steps viz., precipitation, filtration, chromatography etc ( Miyanohara , A et al. PNAS (1983) 80(1): 1-5.; Cregg J. M. et al. Biotechnology (1987) 5:479-485; Gurramkonda, Chandrasekhar et al. (2009) Microbial Cell Factories 8:13).
  • HBsAg is present at an amount of 2-20, 5-18, 7-15 microgram per dose, preferably as a 0.5 mL dosage volume. In one of the embodiments, HBsAg is adsorbed onto aluminium adjuvant, either aluminium hydroxide or aluminium phosphate or a mixture of both. In one of the preferred embodiments, HBsAg is adsorbed onto aluminium phosphate adjuvant. In one of the embodiments, HBsAg is a component of the monovalent or multivalent vaccine composition.
  • Polio antigen is typically inactivated poliomyelitis virus.
  • the poliomyelitis (polio) virus may either be derived from Salk strain (wild strain) or Sabin strain (attenuated strain).
  • IPV antigen includes three wild strains of Salk polioviruses viz., salk type 1 (Mahoney), salk type 2 (MEF) and salk type 3 (Saukett) or the Sabin strains viz., sabin type 1, sabin type 2 and sabin type 3. These viruses are grown on culture medium, harvested, purified and inactivated individually before being combined as an IPV standalone vaccine. Methods of producing inactivated poliomyelitis virus vaccine are well known in the art.
  • polioviruses are grown in suitable cell lines (VERO or MRC5) on microcarriers in bioreactors containing the appropriate cell culture medium for the growth of the virus.
  • the virus is harvested and purified by means of a several downstream steps such as ultrafiltration, diafiltration, one or more chromatography step, followed by their inactivation. Inactivation of viruses is generally achieved by treatment with formaldehyde, however other agents may also be used.
  • the individual viruses (salk or sabin viruses types) are concentrated and mixed to obtain IPV bulk which may be used to prepare a standalone IPV vaccine or combined with other antigens to prepare a multivalent or combination vaccine (Vidor E. and Plotkin, S.A.
  • the polio antigen comprises salk polioviruses viz., salk type 1 (Mahoney), salk type 2 (MEF) and salk type 3 (Saukett).
  • the polio antigen comprises sabin polioviruses viz., sabin type 1, sabin type 2, and sabin type 3.
  • salk type 1 poliovirus is present in an amount of 10-50, 15-45, 20-40, 30-40, or more typically 40 DU (D antigen units) per dose, preferably as a 0.5 mL dosage volume.
  • salk type 2 poliovirus is present in an amount of 2-15, 5-10, or more typically 8 DU per dose, preferably as a 0.5 mL dosage volume.
  • salk type 3 poliovirus is present in an amount of 8-40, 15-35, 25- 35 or more typically 32 DU per dose, preferably as a 0.5 mL dosage volume.
  • the salk polioviruses viz., salk type 1, salk type 2 and salk type 3 are present in an amount of 40-8-32 DU respectively per dose, preferably as a 0.5 mL dosage volume.
  • polioviruses are not adsorbed onto any adjuvant. In another embodiment, the polioviruses are adsorbed onto aluminium adjuvant, either aluminium hydroxide, aluminium phosphate or a mixture of both. In one of the embodiments, IPV is a component of the monovalent or multivalent vaccine composition.
  • HAV hepatitis A virus
  • SP Streptococcus pneumoniae
  • NM Neisseria meningitidis antigen
  • a rotavirus (RV) antigen such as an inactivated rotavirus or an immunogenic protein of rotavirus
  • a flavivirus (FV) antigen such as a Japanese encephalitis virus, dengue virus, west nile virus
  • HPV human papillomavirus virus
  • VLP virus like particle
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, and one or more antigens, wherein the formaldehyde is present in an amount of less than 0.0025%.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, and one or more antigens selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), flavivirus (FV), and human papillomavirus (HPV), wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, 0.0002% to 0.0016%, 0.0002% to 0.0014%, or 0.0002% to 0.0012%.
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, and one or more antigens selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV), wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, 0.0002% to 0.0016%, 0.0002% to 0.0014%, or 0.0002% to 0.0012%.
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV Haemophilus influenzae type b
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a diphtheria (D) antigen, preferably diphtheria toxoid.
  • D diphtheria
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a tetanus (T) antigen, preferably tetanus toxoid.
  • T tetanus
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a pertussis (P) antigen.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a pertussis (P) antigen, preferably whole cell pertussis (wP).
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a pertussis (P) antigen, preferably one or more components of pertussis i.e., acellular pertussis (aP).
  • P pertussis
  • a vaccine composition of the invention comprises 2-phenoxyethnaol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a Hib antigen, preferably Haemophilus influenzae type b polysaccharide conjugated to a carrier protein.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a hepatitis B (HepB) antigen, preferably the surface protein of hepatitis B virus such as Hepatitis B surface Antigen (HBsAg).
  • HepB hepatitis B
  • HBsAg Hepatitis B surface Antigen
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and a polio (IPV) antigen, preferably, an inactivated poliomyelitis virus derived from salk strains or sabin strains.
  • IPV polio
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least two antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least three antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least four antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least five antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least six antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least seven antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least eight antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least nine antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least ten antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • a vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and at least eleven antigens selected from the group comprising of D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV.
  • the vaccine composition of the invention comprises 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and D, T, P, HepB, Hib, IPV, HAV, SP, NM, RV, FV and HPV antigens.
  • a vaccine composition of the invention comprises 2- phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and an antigen selected from the group comprising of diphtheria (D), tetanus (T) and whole cell pertussis (wP).
  • D diphtheria
  • T tetanus
  • WP whole cell pertussis
  • a vaccine composition of the invention comprises 2- phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and an antigen selected from the group comprising of diphtheria (D), tetanus (T), whole cell pertussis (wP), and hepatitis B (HepB).
  • D diphtheria
  • T tetanus
  • wP whole cell pertussis
  • HepB hepatitis B
  • a vaccine composition of the invention comprises 2- phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and an antigen selected from the group comprising of diphtheria (D), tetanus (T), whole cell pertussis (wP), hepatitis B (HepB), and Haemophilus influenzae type b (Hib).
  • D diphtheria
  • T tetanus
  • wP whole cell pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • a vaccine composition of the invention comprises 2- phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025% or in an amount from 0.0002% to 0.0024% and an antigen selected from the group comprising of diphtheria (D), tetanus (T), whole cell pertussis (wP), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV).
  • D diphtheria
  • T tetanus
  • wP whole cell pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • a vaccine composition of the invention comprises 2- phenoxyethnaol and formaldehyde, wherein the formaldehyde is present in an amount of 0.0002% to 0.0014% and the 2-phenoxyethanol is present in an amount from 0.5% to 0.6%, and an antigen selected from the group comprising of diphtheria (D), tetanus (T), whole cell pertussis (wP), hepatitis B (HepB), Haemophilus influenzae type b (Hib), and polio (IPV).
  • D diphtheria
  • T tetanus
  • wP whole cell pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • the invention is not limited to any specific method of preparation of the vaccine compositions. Methods of preparation of vaccine compositions are well known to a person skilled in the art. There are several ways in which the antigens may be formulated or combined. Some antigens may be pre-adsorbed (separate adsorption), some antigens may be adsorbed during the steps of addition of one or more antigens (sequential adsorption), while some antigens remain un-adsorbed or not adsorbed to an adjuvant.
  • compositions comprising different antigens may be prepared by any of the methods described in the prior art, for example, the methods described in W093/24148; W02005/089794; W02008/028956;W098/00167; IN 524/KOL/2003; W02010046934; W02010046935;
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, exogenously to the vaccine composition.
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, endogenously to the vaccine composition.
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethnaol, formaldehyde in an amount from 0.0002% to 0.0024%, %, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding partial amount of 2-phenoxyethanol, formaldehyde, or both, endogenously to the vaccine composition.
  • the invention relates to a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, %, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding partial amount of 2-phenoxyethnaol, formaldehyde, or both, exogenously to the vaccine composition.
  • the method comprises a step of adding 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, or both, after adding all the antigens or before adding any of the antigens of the vaccine composition.
  • the method comprises a step of adding 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, or both, at any intermediate step during the addition of any one of the antigens of the vaccine composition.
  • the method comprises a step of adding 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, or both, pre-mixed with one or more of the antigens of the vaccine composition.
  • the method comprises a step of adding 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, or both, after the addition of the first antigen or pre-mixed with the first antigen.
  • a vaccine composition comprising 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount of less than 0.0025%.
  • a vaccine composition comprising 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.0024%.
  • a vaccine composition comprising 2-phenoxyethanol and formaldehyde, wherein the formaldehyde is present in an amount from 0.0002% to 0.002%.
  • the vaccine composition comprises at least one antigen selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), flavivirus (FV), and human papillomavirus (HPV).
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • HAV hepatitis A virus
  • SP Streptococcus pneumoniae
  • NM Neisseria meningitidis
  • RV rotavirus
  • FV flavivirus
  • HPV human papillomavirus
  • diphtheria antigen is a diphtheria toxoid in an amount from 5 to 50, 10 to 30, or 10 to 20 Lf.
  • tetanus antigen is a tetanus toxoid in an amount from 2 to 30, 5 to 20, 5 to 15, or 5 to 10 Lf.
  • pertussis antigen is either whole cell pertussis (wP) or acellular pertussis (aP).
  • the vaccine composition according to paragraph 6 wherein the hepatitis B antigen is present in an amount from 2 to 20, 5 to 18, or 7 to 15 pg. 12. The vaccine composition according to paragraph 6, wherein the Haemophilus influenzae type b antigen is present in an amount from 2 to 20, 5 to 18, or 7 to 15 pg.
  • the vaccine composition according to paragraph 6, wherein the polio antigen is an inactivated poliomyelitis virus derived from either a salk strain or a sabin strain.
  • salk strains are salk type 1 (Mahoney), salk type 2 (MEF), and salk type 3 (Saukett).
  • the vaccine composition comprises the diphtheria antigen in an amount from 10 to 20 Lf, the tetanus antigen in an amount from 5 to 10 Lf, the whole cell pertussis antigen in an amount from 10 to 25 IOU, the hepatitis B antigen in an amount from 7 to 15 pg, the haemophilus influenzae type b antigen in an amount from 7 to 15 pg, and the polio antigen comprising salk type 1 (Mahoney), salk type 2 (MEF), and salk type 3 (Saukett) in an amount of 10 to 50 DU, 2 to 15 DU and 8 to 40 DU respectively.
  • the vaccine composition comprises the diphtheria antigen in an amount from 10 to 20 Lf, the tetanus antigen in an amount from 5 to 10 Lf, the whole cell pertussis antigen in an amount from 10 to 25 IOU, the hepatitis B antigen in an amount from 7 to 15 pg, the haemophilus influenzae type
  • a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, endogenously to the vaccine composition.
  • a method of preparing a vaccine composition comprising 2-phenoxyethanol, formaldehyde in an amount from 0.0002% to 0.0024%, 0.0002% to 0.002%, 0.0002% to 0.0018%, preferably 0.0002% to 0.0016%, or more preferably 0.0002% to 0.0014%, wherein the method comprises a step of adding 2-phenoxyethanol, formaldehyde, or both, exogenously to the vaccine composition.
  • the method further comprises a step of adding at least one antigen selected from the group comprising of diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), Haemophilus influenzae type b (Hib), polio (IPV), hepatitis A virus (HAV), Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), rotavirus (RV), flavi virus (FV), human papillomavirus (HPV).
  • D diphtheria
  • T tetanus
  • P pertussis
  • HepB hepatitis B
  • Hib Haemophilus influenzae type b
  • IPV polio
  • HAV hepatitis A virus
  • SP Streptococcus pneumoniae
  • NM Neisseria meningitidis
  • RV rotavirus
  • FV flavi virus
  • HPV human papillom
  • the estimated potency is not less than 4.0 IU/SHD (Ref: IP2018// J /z Eur 2.7.7/WHO TRS 941 Annex 6).
  • mice At least 50% of mice should show seroconversion (Ref: Ph Eur 01/2019:1219)
  • Type 1 40 DU/dose
  • Type 2 8 DU/dose
  • Type 3 32 DU/dose when measured through a suitable immunochemical assay (Ref: IP2018// J /z Eur 2.7.1/WHO TRS 910 Annex 2).
  • the variability between the theoretical D antigen units (DU) 40:8:32 for type 1, type 2, and type 3 respectively and the reported DU for three IPV types in the table above are within in the analytical variability for D antigen ELISA and are considered indicative of stable composition. Note:
  • SHD Single Human Dose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une combinaison de conservateurs pour composition ou formulation de vaccin, plus particulièrement une combinaison de 2-phénoxyéthanol et de formaldéhyde et un procédé de préparation d'une composition de vaccin comprenant du 2-phénoxyéthanol et du formaldéhyde. En particulier, l'invention concerne une composition de vaccin comprenant du 2-phénoxyéthanol (2-PE) et du formaldéhyde, le formaldéhyde étant présent en une quantité inférieure à 0,0025 %.
PCT/IB2021/051848 2020-03-05 2021-03-05 Combinaison de conservateurs pour composition de vaccin Ceased WO2021176409A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041009494 2020-03-05
IN202041009494 2020-03-05

Publications (1)

Publication Number Publication Date
WO2021176409A1 true WO2021176409A1 (fr) 2021-09-10

Family

ID=75377832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/051848 Ceased WO2021176409A1 (fr) 2020-03-05 2021-03-05 Combinaison de conservateurs pour composition de vaccin

Country Status (1)

Country Link
WO (1) WO2021176409A1 (fr)

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135662A (en) 1961-01-05 1964-06-02 Burroughs Wellcome Co Diphtheria toxoid preparation and its production
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
WO1993024148A1 (fr) 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Vaccins combines contenant des antigenes de surface du virus de l'hepatite b et d'autres antigenes
US5693326A (en) 1993-09-22 1997-12-02 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
WO1998000167A1 (fr) 1996-07-02 1998-01-08 Connaught Laboratories Limited Vaccins dct-polio multivalents
WO1998034594A1 (fr) 1997-02-06 1998-08-13 Merck & Co., Inc. Conservateurs sans thimerosal pour vaccins
US6060067A (en) 1992-07-31 2000-05-09 Medeva Pharma Limited Process for the preparation of tetanus toxoid vaccine
WO2005089794A2 (fr) 2004-03-15 2005-09-29 Novartis Vaccines And Diagnostics Srl Vaccins de combinaison a faible dose de conjugue h.influenza type b
WO2006002502A1 (fr) 2004-07-05 2006-01-12 Fundação Butantan Methode d'obtention d'un nouveau vaccin cellulaire contre la coqueluche
WO2006100108A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Processus de fermentation servant a la production de toxine diphterique
WO2007026249A2 (fr) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vaccination multiple comprenant des meningocoques du serogroupe c
WO2008020322A2 (fr) 2006-08-15 2008-02-21 Novatris Ag Vaccins de combinaison avec agent de conservation à base de 1-hydroxy-2-phénoxyéthane
WO2008028956A1 (fr) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccin
WO2010046934A1 (fr) 2008-10-24 2010-04-29 Panacea Biotec Ltd. Vaccin combiné notamment contre la coqueluche (vaccin cellulaire entier)
WO2010046935A1 (fr) 2008-10-24 2010-04-29 Panacea Biotec Ltd. Vaccin combiné notamment contre la coqueluche acellulaire
WO2013107988A1 (fr) 2012-01-17 2013-07-25 Sanofi Pasteur Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium
WO2017048038A1 (fr) 2015-09-16 2017-03-23 Lg Life Sciences Ltd. Composition de vaccin combinée pour administration multiple
US20180000923A1 (en) * 2015-02-19 2018-01-04 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2020021416A1 (fr) 2018-07-21 2020-01-30 Biological E Limited Formulations de vaccin comprenant un système conservateur

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135662A (en) 1961-01-05 1964-06-02 Burroughs Wellcome Co Diphtheria toxoid preparation and its production
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
WO1993024148A1 (fr) 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Vaccins combines contenant des antigenes de surface du virus de l'hepatite b et d'autres antigenes
US6060067A (en) 1992-07-31 2000-05-09 Medeva Pharma Limited Process for the preparation of tetanus toxoid vaccine
US5693326A (en) 1993-09-22 1997-12-02 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
WO1998000167A1 (fr) 1996-07-02 1998-01-08 Connaught Laboratories Limited Vaccins dct-polio multivalents
WO1998034594A1 (fr) 1997-02-06 1998-08-13 Merck & Co., Inc. Conservateurs sans thimerosal pour vaccins
WO2005089794A2 (fr) 2004-03-15 2005-09-29 Novartis Vaccines And Diagnostics Srl Vaccins de combinaison a faible dose de conjugue h.influenza type b
WO2006002502A1 (fr) 2004-07-05 2006-01-12 Fundação Butantan Methode d'obtention d'un nouveau vaccin cellulaire contre la coqueluche
WO2006100108A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Processus de fermentation servant a la production de toxine diphterique
WO2007026249A2 (fr) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vaccination multiple comprenant des meningocoques du serogroupe c
WO2008020322A2 (fr) 2006-08-15 2008-02-21 Novatris Ag Vaccins de combinaison avec agent de conservation à base de 1-hydroxy-2-phénoxyéthane
WO2008028956A1 (fr) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccin
WO2010046934A1 (fr) 2008-10-24 2010-04-29 Panacea Biotec Ltd. Vaccin combiné notamment contre la coqueluche (vaccin cellulaire entier)
WO2010046935A1 (fr) 2008-10-24 2010-04-29 Panacea Biotec Ltd. Vaccin combiné notamment contre la coqueluche acellulaire
WO2013107988A1 (fr) 2012-01-17 2013-07-25 Sanofi Pasteur Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium
US20180000923A1 (en) * 2015-02-19 2018-01-04 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2017048038A1 (fr) 2015-09-16 2017-03-23 Lg Life Sciences Ltd. Composition de vaccin combinée pour administration multiple
WO2020021416A1 (fr) 2018-07-21 2020-01-30 Biological E Limited Formulations de vaccin comprenant un système conservateur

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Manual for the production and control of vaccines: pertussis vaccine", 1977, WORLD HEALTH ORGANIZATION
AWYER, LEIGH A. ET AL., VACCINE, vol. 12, 1994, pages 851 - 856
CHU, CHIAYUNG ET AL., INFECTION AND IMMUNITY, vol. 40, no. 1, 1983, pages 245 - 256
CREGG J. M. ET AL., BIOTECHNOLOGY, vol. 5, 1987, pages 479 - 485
FRATELLI, FERNANDO ET AL., BIOTECHNOLOGY PROGRESS, vol. 26, 2010, pages 88 - 92
GRAY GR, METHODS ENZYMOLOGY, vol. 50, 1978, pages 155 - 160
GUPTA, R.K. ET AL., VACCINE, vol. 4, 1986, pages 185 - 190
GUPTA, R.K. ET AL., VACCINE, vol. 6, 1988, pages 491 - 496
GURRAMKONDA, CHANDRASEKHAR ET AL., MICROBIAL CELL FACTORIES, vol. 8, 2009, pages 13
HEKKENS, F.E.N. ET AL., JOURNAL OF BIOLOGICAL STANDARDIZATION, vol. 9, 1981, pages 277 - 285
J BIOL STAND, vol. 17, 1987, pages 87 - 98
LAFERRIERE, CRAIG, GLYCOCONJUGATE JOURNAL, vol. 28, 2011, pages 463 - 472
LEES, ANDREW ET AL., VACCINE, vol. 14, no. 3, 1996, pages 190 - 198
MEYER, BRIAN K. ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 96, 2007, pages 3155 - 3167
MIYANOHARA, A ET AL., PNAS, vol. 80, no. 1, 1983, pages 1 - 5
P. W. ANDERSON ET AL., J. IMMUNOL., vol. 137, 1986, pages 1181 - 1186
SCHNEERSON, R. ET AL., J. EXP. MED., vol. 152, 1980, pages 361 - 476
SILVEIRA, I.A. ET AL., VACCINE, vol. 25, 2007, pages 7261 - 7270
THALEN, MARCEL ET AL., VACCINE, vol. 26, 2008, pages 653 - 663
VIDOR E.PLOTKIN, S.A.: "Vaccines", vol. 573-797, 2013, SAUNDERS, article "Poliovirus Vaccine (Inactivated"

Similar Documents

Publication Publication Date Title
RU2634393C2 (ru) Комбинированная вакцина с ацеллюлярным коклюшем
RU2641969C2 (ru) Множественная вакцинация, включающая менингококки серогруппы с
EP2066344B2 (fr) Vaccin combiné du virus de poliomyelite inactivé
US9040058B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
US20100226937A1 (en) Combination vaccines with 1-hydroxy-2-phenoxyethane preservative
RU2613295C2 (ru) Комбинированная вакцина с цельноклеточным коклюшем
KR102607295B1 (ko) 다가 백신 조성물
US12268738B2 (en) Liquid six combined vaccine composition
EP2592137A1 (fr) Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
DE102011122891B4 (de) Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
AU2012261763B2 (en) Multiple vaccination including serogroup C meningococcus
AU2013203663B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
WO2020165920A1 (fr) Composition vaccinale multivalente

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21716541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21716541

Country of ref document: EP

Kind code of ref document: A1